Overall, 54 adult patients presenting with chronic wounds received, in total, 92 topical doses of 1–2 × 106 ABCB5+ MSCs per cm2 wound surface area [68,152], and 16 patients aged 4–36 years suffering from RDEB received 46 intravenous infusions of 2 × 106 ABCB5+ MSCs per kg body weight in total [166]. The gene discussed is ABCB5; the disease is recessive dystrophic epidermolysis bullosa.